New Listeria fears spotlighted as Aduro’s CRS-207 is slapped with partial hold
Nagging fears that Aduro Biotech’s cancer vaccine CRS-207 could trigger serious Listeria infections mushroomed into a severe setback on Monday morning as the biotech reported that it had to halt enrollment in all of its clinical studies using that technology. The partial hold was instituted by the FDA after a patient tested positive for Listeria, which is suspected to be CRS-207, Aduro’s lead cancer vaccine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
